Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events

Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The insights from this study help to inform decisions regarding sequential and salvage treatments.